Clinical study of evaluating tigecycline in high-risk hematologic patients with febrile neutropenia

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-15006934

Enrollment

Unknown

Registered

2015-08-18

Start date

2014-10-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

high-risk hematologic patients with febrile neutropenia

Interventions

Case series:Tigecycline

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Adults over 18 years of age; 2. High-risk hematologic patients with febrile neutropenia(According to IDSA diagnostic criteria of febrile neutropenia, 2010); 3. Patients failed to responde to broad-spectrum antibiotics covering gram negative bacteria and anti- gram positive bacteria antibiotics after treatment course of three days; 4. Informed consent of patients is required.

Exclusion criteria

Exclusion criteria: 1. Patients allergic to tigecycline or tetracycline; 2. Acute liver failure or decompensated chronic liver failure; 3. Pregnant or lactating women.

Design outcomes

Primary

Measure	Time frame
Febrile episode resolution;	—

Secondary

Measure	Time frame
Death;Death resulting from infective cause;Adverse events;Withdrawal due to adverse events;	—

Countries

China

Contacts

Public Contacthongyantong

hongyantong@aliyun.com+86 13958122357

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026